BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [21] First-Line Therapy for untreated locally advanced, inoperable or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    von Amsberg, Gunhild
    Doehn, Christian
    AKTUELLE UROLOGIE, 2024, 55 (05)
  • [22] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [23] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    Advances in Therapy, 2012, 29 : 202 - 217
  • [24] Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma A NICE Single Technology Appraisal
    Kilonzo, Mary
    Hislop, Jenni
    Elders, Andrew
    Fraser, Cynthia
    Bissett, Donald
    McClinton, Samuel
    Mowatt, Graham
    Vale, Luke
    PHARMACOECONOMICS, 2013, 31 (01) : 15 - 24
  • [25] Axitinib as first-line therapy in metastatic renal cell carcinoma
    Nozawa, Masahiro
    Uemura, Hirotsugu
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
  • [26] Tolerability of first-line therapy for metastatic renal cell carcinoma
    Porta, Camillo
    Szczylik, Cezary
    CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
  • [27] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
    Atkins, Michael B.
    Tannir, Nizar M.
    CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
  • [28] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [29] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
  • [30] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
12345